Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.

导出 OA

翻译打印收藏纠错

作者： Andrew J,Cowan ^[1] ; Philip A,Stevenson ^[1] ; Ryan D,Cassaday ^[1] ; Solomon A,Graf ^[1] ; Jonathan R,Fromm ^[2] ; David,Wu ^[2] ; Leona A,Holmberg ^[1] ; Brian G,Till ^[1] ; Thomas R,Chauncey ^[3] ; Stephen D,Smith ^[1] ; Mary,Philip ^[1] ; Johnnie J,Orozco ^[1] ; Andrei R,Shustov ^[1] ; Damian J,Green ^[1] ; Edward N,Libby ^[4] ; William I,Bensinger ^[1] ; Mazyar,Shadman ^[1] ; David G,Maloney ^[5] ; Oliver W,Press ^[1] ; Ajay K,Gopal ^[6]

作者单位： Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington. ^[1] Marrow Transplant Unit, Department of Laboratory Medicine, University of Washington, Seattle, Washington. ^[2] Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington; VA Puget Sound Health Care System, Seattle, Washington. ^[3] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington. ^[4] Transplantation Biology Department, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. ^[5] Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington. Electronic address: agopal@u.washington.edu. ^[6]

关键词 Mantle cell lymphoma Minimal residual disease Predictors Survival Transplantation